[Antibiotics against myocardial infarction? The risk of resistance development must be considered].
Kallings
I
I
Smittskyddsinstitutet, Stockholm.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002690:Chlamydia Infections / Q000150:complications / Q000188:drug therapy; D016993:Chlamydophila pneumoniae / Q000187:drug effects / Q000276:immunology; D003324:Coronary Artery Disease / Q000150:complications / Q000382:microbiology / Q000473:pathology; D004352:Drug Resistance, Microbial; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control*; D012307:Risk Factors; D014657:Vasculitis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology
D000900:Anti-Bacterial Agents
Antibiotika mot hjärtinfarkt? Faran för resistensutveckling måste dock beaktas.